Seminars in Hematology
Volume 44, Issue 2 , Pages 98-105 , April 2007

Sex Hormones and Thrombosis

  • Henry G. Watson

      Affiliations

    • Corresponding Author InformationAddress correspondence to Henry G. Watson, MD, Aberdeen Royal Infirmary, Foresterhill, Aberdeen AB25 2ZN, Scotland, UK.

References 

  1. Wu O, Robertson L, Twaddle S, Lowe G, Clark P, Walker I, et al. Screening for thrombophilia in high-risk situations: A meta-analysis and cost-effectiveness analysis. Br J Haematol. 2005;131:80–90
  2. United Nations Population Division. World Contraceptive Use 2001. New York, NY: United Nations; 2002;
  3. Beral V, Banks E, Reeves G, Appleby P. Use of HRT and the subsequent risk of cancer. J Epidemiol Biostat. 1999;4:191–210
  4. Jordan WM. Pulmonary embolism. Br Med J. 1961;2:1146–1147
  5. Boyce J, Fawcett JW, Noall EW. Coronary thrombosis and Conovide. Lancet. 1963;1:111
  6. Lorentz I. Parietal lesions and Enavid. Br Med J. 1962;2:1191-1191
  7. Daly E, Vessey MP, Hawkins MM, Carson JL, Gough P, Marsh S. Risk of venous thromboembolism in users of hormone replacement therapy. Lancet. 1996;348:977–980
  8. Grodstein F, Stampfer MJ, Goldhaber SZ, Manson JE, Colditz GA, Speizer FE, et al. Prospective study of exogenous hormones and risk of pulmonary embolism in women. Lancet. 1996;348:983–987
  9. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women’s Health Initiative randomized controlled trial. JAMA. 2002;288:321–333
  10. Meade TW, Haines AP, North WR, Chakrabarti R, Howarth DJ, Stirling Y. Haemostatic, lipid, and blood-pressure profiles of women on oral contraceptives containing 50 microgram or 30 microgram oestrogen. Lancet. 1977;2:948–951
  11. Quehenberger P, Loner U, Kapiotis S, Handler S, Schneider B, Huber J, et al. Increased levels of activated factor VII and decreased plasma protein S activity and circulating thrombomodulin during use of oral contraceptives. Thromb Haemost. 1996;76:729–734
  12. Scarabin PY, Plu-Bureau , Zitoun D, Bara L, Guize L, Samama MM. Changes in haemostatic variables induced by oral contraceptives containing 50 micrograms or 30 micrograms oestrogen: Absence of dose-dependent effect on PAI-1 activity. Thromb Haemost. 1995;74:928–932
  13. World Health Organization. A multicentre study of coagulation and haemostatic variables during oral contraception: variations with four formulations. Br J Obstet Gynaecol. 1991;98:1117–1128
  14. Rosing J, Tans G, Nicolaes GA, Thomassen MC, van OR, van der Ploeg PM, et al. Oral contraceptives and venous thrombosis: Different sensitivities to activated protein C in women using second- and third-generation oral contraceptives. Br J Haematol. 1997;97:233–238
  15. Rosing J, Middeldorp S, Curvers J, Christella M, Thomassen LG, Nicolaes GA, et al. Low-dose oral contraceptives and acquired resistance to activated protein C: A randomised cross-over study. Lancet. 1999;354:2036–2040
  16. Tans G, Curvers J, Middeldorp S, Thomassen MC, Meijers JC, Prins MH, et al. A randomized cross-over study on the effects of levonorgestrel- and desogestrel-containing oral contraceptives on the anticoagulant pathways. Thromb Haemost. 2000;84:15–21
  17. Acs N, Vajo Z, Miklos Z, Siklosi G, Paulin F, Felicetta JV, et al. The effects of postmenopausal hormone replacement therapy on hemostatic variables: A meta-analysis of 46 studies. Gynecol Endocrinol. 2002;16:335–346
  18. Middeldorp S, Meijers JC, van den Ende AE, van EA, Bouma BN, Tans G, et al. Effects on coagulation of levonorgestrel- and desogestrel-containing low dose oral contraceptives: A cross-over study. Thromb Haemost. 2000;84:4–8
  19. Bloemenkamp KW, Rosendaal FR, Helmerhorst FM, Vandenbroucke JP. Higher risk of venous thrombosis during early use of oral contraceptives in women with inherited clotting defects. Arch Intern Med. 2000;160:49–52
  20. Herings RM, Urquhart J, Leufkens HG. Venous thromboembolism among new users of different oral contraceptives. Lancet. 1999;354:127–128
  21. Bloemenkamp KW, Rosendaal FR, Helmerhorst FM, Buller HR, Vandenbroucke JP. Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen. Lancet. 1995;346:1593–1596
  22. Gerstman BB, Piper JM, Tomita DK, Ferguson WJ, Stadel BV, Lundin FE. Oral contraceptive estrogen dose and the risk of deep venous thromboembolic disease. Am J Epidemiol. 1991;133:32–37
  23. Oral contraception and thrombo-embolic disease. J R Coll Gen Pract. 1967;13:267–279
  24. Gomes MP, Deitcher SR. Risk of venous thromboembolic disease associated with hormonal contraceptives and hormone replacement therapy: A clinical review. Arch Intern Med. 2004;164:1965–1976
  25. Koster T, Small RA, Rosendaal FR, Helmerhorst FM. Oral contraceptives and venous thromboembolism: A quantitative discussion of the uncertainties. J Intern Med. 1995;238:31–37
  26. Gerstman BB, Piper JM, Freiman JP, Tomita DK, Kennedy DL, Ferguson WJ, et al. Oral contraceptive oestrogen and progestin potencies and the incidence of deep venous thromboembolism. Int J Epidemiol. 1990;19:931–936
  27. Bloemenkamp KW, Rosendaal FR, Buller HR, Helmerhorst FM, Colly LP, Vandenbroucke JP. Risk of venous thrombosis with use of current low-dose oral contraceptives is not explained by diagnostic suspicion and referral bias. Arch Intern Med. 1999;159:65–70
  28. Lidegaard O, Edstrom B, Kreiner S. Oral contraceptives and venous thromboembolism: A five-year national case-control study. Contraception. 2002;65:187–196
  29. Jick H, Jick SS, Gurewich V, Myers MW, Vasilakis C. Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components. Lancet. 1995;346:1589–1593
  30. World Health Organization. Effect of different progestogens in low oestrogen oral contraceptives on venous thromboembolic disease (World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception). Lancet. 1995;346:1582–1588
  31. Hennessy S, Berlin JA, Kinman JL, Margolis DJ, Marcus SM, Strom BL. Risk of venous thromboembolism from oral contraceptives containing gestodene and desogestrel versus levonorgestrel: A meta-analysis and formal sensitivity analysis. Contraception. 2001;64:125–133
  32. Kemmeren JM, Algra A, Grobbee DE. Third generation oral contraceptives and risk of venous thrombosis: Meta-analysis. BMJ. 2001;323:131–134
  33. Royal College of Obstetricians and Gynaecologists. Venous thromboembolism and hormonal contraception. Guideline. 2004;40:1–13
  34. Jick SS, Jick H. Cerebral venous sinus thrombosis in users of four hormonal contraceptives: Levonorgestrel-containing oral contraceptives, norgestimate-containing oral contraceptives, desogestrel-containing oral contraceptives and the contraceptive patch. Contraception. 2006;74:290–292
  35. Vasilakis-Scaramozza C, Jick H. Risk of venous thromboembolism with cyproterone or levonorgestrel contraceptives. Lancet. 2001;358:1427–1429
  36. Seaman HE, de Vries CS, Farmer RD. Venous thromboembolism associated with cyproterone acetate in combination with ethinyloestradiol (Dianette): Observational studies using the UK General Practice Research Database. Pharmacoepidemiol Drug Saf. 2004;13:427–436
  37. Spitzer WO. Cyproterone acetate with ethinylestradiol as a risk factor for venous thromboembolism: An epidemiological evaluation. J Obstet Gynaecol Can. 2003;25:1011–1018
  38. Pearce HM, Layton D, Wilton LV, Shakir SA. Deep vein thrombosis and pulmonary embolism reported in the Prescription Event Monitoring Study of Yasmin. Br J Clin Pharmacol. 2005;60:98–102
  39. Heinemann LA, Dinger J. Safety of a new oral contraceptive containing drospirenone. Drug Saf. 2004;27:1001–1018
  40. Jick SS, Kaye JA, Russmann S, Jick H. Risk of nonfatal venous thromboembolism in women using a contraceptive transdermal patch and oral contraceptives containing norgestimate and 35 μg of ethinyl estradiol. Contraception. 2006;73:223–228
  41. Vasilakis C, Jick H, del MM-M. Risk of idiopathic venous thromboembolism in users of progestagens alone. Lancet. 1999;354:1610–1611
  42. Poulter NR, Chang CL, Farley TM, Meirik O. Risk of cardiovascular diseases associated with oral progestagen preparations with therapeutic indications. Lancet. 1999;354:1610
  43. World Health Organization. A multinational case-control study of cardiovascular disease and steroid hormone contraceptives. J Clin Endocrinol Metab. 1995;48:1513–1547
  44. Grady D, Wenger NK, Herrington D, Khan S, Furberg C, Hunninghake D, et al. Postmenopausal hormone therapy increases risk for venous thromboembolic disease (The Heart and Estrogen/progestin Replacement Study). Ann Intern Med. 2000;132:689–696
  45. Beral V, Banks E, Reeves G. Evidence from randomised trials on the long-term effects of hormone replacement therapy. Lancet. 2002;360:942–944
  46. Jick H, Derby LE, Myers MW, Vasilakis C, Newton KM. Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogens. Lancet. 1996;348:981–983
  47. Perez GS, Garcia Rodriguez LA, Castellsague J, Duque OA. Hormone replacement therapy and risk of venous thromboembolism: Population based case-control study. BMJ. 1997;314:796–800
  48. Varas-Lorenzo C, Garcia-Rodriguez LA, Cattaruzzi C, Troncon MG, Agostinis L, Perez-Gutthann S. Hormone replacement therapy and the risk of hospitalization for venous thromboembolism: A population-based study in southern Europe. Am J Epidemiol. 1998;147:387–390
  49. Douketis JD, Julian JA, Kearon C, Anderson DR, Crowther MA, Bates SM, et al. Does the type of hormone replacement therapy influence the risk of deep vein thrombosis? (A prospective case-control study). J Thromb Haemost. 2005;3:943–948
  50. Smith NL, Heckbert SR, Lemaitre RN, Reiner AP, Lumley T, Weiss NS, et al. Esterified estrogens and conjugated equine estrogens and the risk of venous thrombosis. JAMA. 2004;292:1581–1587
  51. Scarabin PY, Oger E, Plu-Bureau G. Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk. Lancet. 2003;362:428–432
  52. Straczek C, Oger E, Yon de Jonage-Canonico MB, Plu-Bureau G, Conard J, Meyer G, et al. Prothrombotic mutations, hormone therapy, and venous thromboembolism among postmenopausal women: Impact of the route of estrogen administration. Circulation. 2005;112:3495–3500
  53. World Health Organization. Venous thromboembolic disease and combined oral contraceptives: Results of international multicentre case-control study (World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception). Lancet. 1995;346:1575–1582
  54. Suissa S, Spitzer WO, Rainville B, Cusson J, Lewis M, Heinemann L. Recurrent use of newer oral contraceptives and the risk of venous thromboembolism. Hum Reprod. 2000;15:817–821
  55. Abdollahi M, Cushman M, Rosendaal FR. Obesity: risk of venous thrombosis and the interaction with coagulation factor levels and oral contraceptive use. Thromb Haemost. 2003;89:493–498
  56. Cushman M, Kuller LH, Prentice R, Rodabough RJ, Psaty BM, Stafford RS, et al. Estrogen plus progestin and risk of venous thrombosis. JAMA. 2004;292:1573–1580
  57. Farmer RD, Lawrenson RA, Thompson CR, Kennedy JG, Hambleton IR. Population-based study of risk of venous thromboembolism associated with various oral contraceptives. Lancet. 1997;349:83–88
  58. Farmer RD, Lawrenson RA, Todd JC, Williams TJ, MacRae KD, Tyrer F, et al. A comparison of the risks of venous thromboembolic disease in association with different combined oral contraceptives. Br J Clin Pharmacol. 2000;49:580–590
  59. Hoibraaten E, Qvigstad E, Arnesen H, Larsen S, Wickstrom E, Sandset PM. Increased risk of recurrent venous thromboembolism during hormone replacement therapy—Results of the randomized, double-blind, placebo-controlled Estrogen in Venous Thromboembolism Trial (EVTET). Thromb Haemost. 2000;84:961–967
  60. Vessey MP, Doll R, Fairbairn AS, Glober G. Postoperative thromboembolism and the use of oral contraceptives. Br Med J. 1970;3:123–126
  61. Royal College of Obstetricians and Gynaecologists. In: Hormone Replacement Therapy and Venous Thromboembolism. London, UK: Royal College of Obstetricians and Gynaecologists; 2004;p. 1–9Guideline No 19
  62. Baglin T, Luddington R, Brown K, Baglin C. Incidence of recurrent venous thromboembolism in relation to clinical and thrombophilic risk factors: Prospective cohort study. Lancet. 2003;362:523–526
  63. Martinelli I, Mannucci PM, Taioli E, Rossi V, Crosti F, et al. Different risks of thrombosis in four coagulation defects associated with inherited thrombophilia: A study of 150 families. De S, V Blood. 1998;92:2353–2358
  64. Simioni P, Sanson BJ, Prandoni P, Tormene D, Friederich PW, Girolami B, et al. Incidence of venous thromboembolism in families with inherited thrombophilia. Thromb Haemost. 1999;81:198–202
  65. Vandenbroucke JP, Koster T, Briet E, Reitsma PH, Bertina RM, Rosendaal FR. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet. 1994;344:1453–1457
  66. Rosendaal FR, Koster T, Vandenbroucke JP, Reitsma PH. High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance). Blood. 1995;85:1504–1508
  67. Martinelli I, Taioli E, Bucciarelli P, Akhavan S, Mannucci PM. Interaction between the G20210A mutation of the prothrombin gene and oral contraceptive use in deep vein thrombosis. Arterioscler Thromb Vasc Biol. 1999;19:700–703
  68. Wu O, Robertson L, Langhorne P, Twaddle S, Lowe GD, Clark P, et al. Oral contraceptives, hormone replacement therapy, thrombophilias and risk of venous thromboembolism: A systematic review (The Thrombosis: Risk and Economic Assessment of Thrombophilia Screening (TREATS) study). Thromb Haemost. 2005;94:17–25
  69. Lowe G, Woodward M, Vessey M, Rumley A, Gough P, Daly E. Thrombotic variables and risk of idiopathic venous thromboembolism in women aged 45-64 years (Relationships to hormone replacement therapy). Thromb Haemost. 2000;83:530–535

PII: S0037-1963(07)00005-4

doi: 10.1053/j.seminhematol.2007.01.004

Seminars in Hematology
Volume 44, Issue 2 , Pages 98-105 , April 2007

Article Tools